☆ 4.6 Review

Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials

WORLD JOURNAL OF SURGICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer

Adriaan Vanderstichele et al.

Summary: Objective. This study aimed to compare the effectiveness of olaparib monotherapy and chemotherapy in patients with platinum-sensitive or platinum-resistant ovarian cancer. The results showed that olaparib monotherapy had a similar overall objective response rate to chemotherapy in relapsed ovarian cancer. In platinum-resistant cases, olaparib had a tendency to achieve a higher objective response rate and longer time to treatment failure compared to chemotherapy. Furthermore, olaparib showed better efficacy than chemotherapy in heavily pretreated patients with platinum-resistant ovarian cancer.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study

Elizabeth M. Swisher et al.

Summary: This study examines the efficacy of the PARP inhibitor veliparib in ovarian cancer patients. The results show that veliparib, when combined with chemotherapy and used as maintenance therapy, can extend progression-free survival and demonstrate higher objective response rates in certain subgroups. These findings provide new opportunities for patients who do not meet the criteria for frontline PARP inhibitor maintenance therapy.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Nicoletta Colombo et al.

Summary: The combination of cediranib and olaparib did not improve the progression-free survival (PFS) compared to chemotherapy in heavily pretreated platinum-resistant ovarian cancer patients. However, this oral doublet is still an effective option for this difficult-to-treat population.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

European cancer mortality predictions for the year 2022 with focus on ovarian cancer

M. Dalmartello et al.

Summary: Cancer mortality rates in Europe have been decreasing over the last three decades. Lung cancer and ovarian cancer rates have decreased, while stomach cancer, colorectal cancer, breast cancer, and prostate cancer rates have shown significant declines. Leukemia and uterine cancer mortality rates have also decreased.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Rebecca Kristeleit et al.

Summary: In patients with BRCA1 or BRCA2 mutated ovarian carcinoma, rucaparib demonstrated better progression-free survival compared to chemotherapy. The results of this study support rucaparib as an alternative treatment option for patients with relapsed BRCA-mutated ovarian carcinoma.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

Lymphadenectomy in ovarian cancers: a meta-analysis of hazard ratios from randomized clinical trials

Roli Purwar et al.

Summary: The debate on systematic lymphadenectomy in epithelial ovarian cancers was ignited by the LION trial but remains inconclusive. Meta-analysis of randomized controlled trials showed a trend towards improved progression-free survival with lymphadenectomy, but no significant benefit on overall survival. More well-conducted trials are needed for a definitive answer.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Deborah K. Armstrong et al.

Journal of the National Comprehensive Cancer Network (2022)

Add to Collection

Article Oncology

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial

X. H. Wu et al.

Summary: This study demonstrated that maintenance treatment with niraparib significantly reduced the risk of disease progression or death in patients with platinum-sensitive recurrent ovarian cancer, and prolonged progression-free survival compared to placebo. Individualized dosing of niraparib was found to be effective and safe, and should be considered standard practice in this setting.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Oncology

Homologous recombination proficiency in ovarian and breast cancer patients

Justin Fortune Creeden et al.

Summary: The text discussed the importance of homologous recombination and DNA repair for genome maintenance, as well as the impact of genetic variations in essential homologous recombination genes such as BRCA1 and BRCA2 on homologous recombination deficiency (HRD) and potential therapeutic strategies. It also highlighted the need for reliable HRD testing methods, as well as current treatment and research on synthetic lethality in HRD.

BMC CANCER (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Dae-Seok Kim et al.

Summary: PARPi target PARP-1 protein to cause DNA damage in cancer cells, but resistance can develop, requiring further research for optimization. They can also be effective against other cancers, and ongoing clinical trials are evaluating combination therapies and resistance mechanisms.

EXPERIMENTAL AND MOLECULAR MEDICINE (2021)

Add to Collection

Article Oncology

Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort

Lingying Wu et al.

Summary: The SOLO1 study demonstrated that maintenance therapy with olaparib can effectively prolong progression-free survival in Chinese patients with newly diagnosed advanced ovarian cancer, who have a BRCA mutation and are in complete or partial response after platinum-based chemotherapy. Moreover, the treatment showed good safety profile, making it an effective option for patients in this population.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Cell Biology

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival

Fengping Shao et al.

Aging-US (2021)

Add to Collection

Article Oncology

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Susana Banerjee et al.

Summary: The study demonstrated that maintenance therapy with olaparib for 2 years can extend progression-free survival to over 4.5 years in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. These results support the use of maintenance olaparib as a standard of care in this setting.

LANCET ONCOLOGY (2021)

Add to Collection

Review Oncology

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers

Dawn C. Janysek et al.

Summary: Cells are frequently exposed to DNA damaging agents, and the failure of DNA damage repair pathways can lead to mutations and abnormal cell growth, supporting malignant transformation. Mutations in genes like BRCA1 and BRCA2 increase the risk of certain cancers and can result in drug resistance over time.

TRANSLATIONAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andres Poveda et al.

Summary: Olaparib provided a median overall survival benefit of 12.9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Although statistical significance was not reached, these findings are arguably clinically meaningful and support the use of maintenance olaparib in these patients.

LANCET ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Oncology

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

Carol Aghajanian et al.

Summary: In the VELIA/GOG-3005 trial, adding veliparib to carboplatin-paclitaxel and continuing as maintenance improved progression-free survival compared to carboplatin-paclitaxel alone in patients with newly diagnosed ovarian carcinoma. Both investigator assessment and blinded independent central review showed consistent results, supporting the reliability of PFS assessment in ovarian cancer trials.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Richard T. Penson et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Ilary Ruscito et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Review Oncology

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

Michelle McMullen et al.

CANCERS (2020)

Add to Collection

Review Health Care Sciences & Services

Protocol registration issues of systematic review and meta-analysis studies: a survey of global researchers

Gehad Mohamed Tawfik et al.

BMC MEDICAL RESEARCH METHODOLOGY (2020)

Add to Collection

Article Oncology

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Josep M. del Campo et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

R. L. Coleman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

K. Moore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman et al.

LANCET (2017)

Add to Collection

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Eric Pujade-Lauraine et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Ursula A. Matulonis et al.

CANCER (2016)

Add to Collection

Article Oncology

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

Jonathan A. Ledermann et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

M. R. Mirza et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

Shivaani Kummar et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Oncology

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Amit M. Oza et al.

LANCET ONCOLOGY (2015)

Add to Collection

Review Oncology

Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

Ursula A. Matulonis et al.

CANCER (2015)

Add to Collection

Article Oncology

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Jonathan Ledermann et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Oncology

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Stan B. Kaye et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Jonathan Ledermann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Article Medicine, Research & Experimental

Practical methods for incorporating summary time-to-event data into meta-analysis

Jayne F. Tierney et al.

TRIALS (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.